| Outcome Measures: |
Primary: Proportion of patients who met HbA1c < 6.5% without hypoglycaemia, weight gain, or discontinuation due to adverse events at 104 weeks, 104 weeks | Secondary: ∙ Proportion of patients who met HbA1c < 6.5% without hypoglycaemia, weight gain, or discontinuation due to adverse events at 52 weeks, 52 weeks|Proportion of patients who met HbA1c < 7.0% without hypoglycaemia, weight gain, or discontinuation due to adverse events at 104 weeks, 104 weeks|Change in body HbA1c from baseline to week 104, 104 weeks|Change in body weight from baseline to week 104, 104 weeks|Change in systolic blood pressure from baseline to week 104, 104 weeks|Changes in fat and lean mass from baseline to at 104 weeks, 104 weeks | Other: AEs/SAEs, hypoglycemia, GI trouble, urinary tract infection, genital infection, volume depletion, panreatitis, severe cutaneous events, hypersensitivity reactions) * Vital signs * Collection of clinical chemistry/haematology parameters, 104 weeks
|
